Targeting the Interleukin-12/23 Cytokine Family in the Treatment of Psoriatic Disease

2008 ◽  
Vol 12 (6_suppl) ◽  
pp. S1-S10 ◽  
Author(s):  
Neil H. Shear ◽  
Jörg Prinz ◽  
Kim Papp ◽  
Richard G.B. Langley ◽  
Wayne P. Gulliver
Keyword(s):  
Quality Of Life ◽  
Treatment Options ◽  
Dose Finding ◽  
Phase Iii ◽  
Interleukin 12 ◽  
Finding Study ◽  
Ortho Biotech ◽  
Phase Iii Trials ◽  
New Treatment

Psoriasis is a complex systemic immune inflammatory disease whose burden of disease includes poorer quality of life, a high prevalence of serious comorbidities, and a potentially decreased life span—hence the continued need to search for new treatment options. ABT-874 (Abbott Laboratories, Saint-Laurent, QC,) and ustekinumab (CNTO 1275, Ortho Biotech, Toronto, ON) are two monoclonal antibodies against interleukins 12 and 23 (IL-12/23), key mediators of T-cell differentiation in the pathogenesis of psoriasis. The results of a 12-week, phase II, dose-finding study of ABT-874 have been encouraging. More recently, level 1 evidence has emerged for ustekinumab in two placebo-controlled phase III trials, PHOENIX 1 and PHOENIX 2; therapeutic responses to ustekinumab have been maintained up to 76 weeks of follow-up, and quality of life has significantly improved with ustekinumab. Both agents produced few and mild adverse events, and the rates of serious infections and cancers were very low and similar to those of placebo. These promising results strongly confirm the central role of IL-12/23 in psoriasis and its importance as a therapeutic target.

scholarly journals An Alternative to Current Therapies of Functional Dyspepsia: Self-Administrated Transcutaneous Electroacupuncture Improves Dyspeptic Symptoms

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Ting Ji ◽  
Xueliang Li ◽  
Lin Lin ◽  
Liuqin Jiang ◽  
Meifeng Wang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Emptying ◽  
Functional Dyspepsia ◽  
Therapeutic Potential ◽  
Treatment Options ◽  
Treatment Method ◽  
Gastric Accommodation ◽  
Dyspeptic Symptoms ◽  
New Treatment

Functional dyspepsia is of high prevalence with little treatment options. The aim of this study was to develop a new treatment method using self-management transcutaneous electroacupuncture (TEA) for functional dyspepsia (FD). Twenty-eight patients with FD were enrolled and underwent a crossover clinical trial with 2-week TEA at ST36 and PC6 and 2-week sham-TEA at nonacupuncture sham-points. Questionnaires were used to assess symptoms of dyspepsia and quality of life. Physiological testing included gastric emptying and electrogastrography. It was found that (1) TEA but not sham-TEA significantly improved dyspeptic symptoms and 4 domains in quality of life; improvement was also noted in self-rated anxiety and depression scores; (2) gastric emptying was significantly and substantially increased with 2-week TEA but not sham-TEA; and (3) gastric accommodation was also improved with TEA but not sham-TEA, reflected as increased ingested nutrient volumes at the levels of satiety and maximum tolerance. These findings suggest a therapeutic potential of self-administrated TEA method for functional dyspepsia, possibly attributed to improvement in gastric motility.

scholarly journals New treatment options of chronic urticaria

2021 ◽  
Vol 97 (5) ◽  
pp. 266-272
Author(s):  
Bernadett Hidvégi ◽  
◽  
Lilla Mihályi
Keyword(s):  
Quality Of Life ◽  
Chronic Urticaria ◽  
Treatment Options ◽  
Multifactorial Disease ◽  
2Nd Generation ◽  
New Treatment

Chronic urticaria is a multifactorial disease with increasing prevalence, that significantly deteriorates the quality of life of patients. Authors describe the pathomechanism of the disease, and they present the currently available treatment options and the promising future therapies as well. The therapeutic basis of chronic urticaria is the modern, 2nd generation antihistamines in a dosage of even four times higher than the regular one. In therapy resistant cases omalizumab or cyclosporin is advised. There is a growing demand for new medications because the number of those patients , who are non-responders or do not respond adequately to these therapies, is definitely increasing.

scholarly journals Quality of life and functional outcomes with tapentadol prolonged release in chronic musculoskeletal pain: post hoc analysis

2020 ◽  
Author(s):  
Cesar Margarit Ferri ◽  
Silvia Natoli ◽  
Paz Sanz-Ayan ◽  
Alberto Magni ◽  
Carlos Guerrero ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Phase Iii ◽  
Prolonged Release ◽  
Post Hoc Analysis ◽  
Three Phase ◽  
Sf 36 ◽  
Phase Iii Trials ◽  
Post Hoc

Aims: To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. Patients & methods: Post hoc analysis of data from three Phase III trials in patients with osteoarthritis knee pain or low back pain. QOL and functionality changes were assessed by SF-36 scores. Results: All SF-36 subdomain scores improved progressively to week 3 of tapentadol titration and were sustained during 12-week maintenance treatment. Improvements in SF-36 scores were similar between tapentadol dose groups (e.g., 200 to <300 mg vs ≥500 mg), with no greater effect from higher doses. QOL and functionality improvements were consistently greater with tapentadol PR than oxycodone controlled release. Conclusion: Tapentadol PR provides consistent, clinically relevant improvements in QOL and functionality in chronic pain.

Sign in / Sign up

Export Citation Format

Share Document